Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002913 | 0.86 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1EPHX2EPHX1HPGD | |
| SCHEMBL13826063 | 0.86 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1EPHX2MEN1KMT2A | |
| SCHEMBL13825989 | 0.85 | MGLL (0.61) | L3MBTL3L3MBTL1MGLL | |
| SCHEMBL13825970 | 0.84 | MGLL (0.60) | L3MBTL1MEN1KMT2AMGLL | |
| SCHEMBL13826039 | 0.83 | POLB (0.56) | L3MBTL3L3MBTL1EPHX2MEN1KMT2A | |
| SCHEMBL16000493 | 0.82 | LMNA (0.64) | L3MBTL3L3MBTL1EPHX2MEN1GAA | |
| SCHEMBL16000516 | 0.82 | L3MBTL1 (0.61) | L3MBTL1MEN1GAAHTTKMT2A | |
| Hydrochloric Acid SCHEMBL6276058 | 0.82 | EPHX1 (0.66) | L3MBTL3L3MBTL1EPHX2MEN1KMT2A | |
| SCHEMBL16000492 | 0.81 | LMNA (0.66) | MEN1KMT2AHPGDMGLL | |
| SCHEMBL13825969 | 0.81 | KMT2A (0.49) | L3MBTL3L3MBTL1EPHX2MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | L3MBTL3 4679/4885L3MBTL1 3948/4885EPHX2 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.